-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Warby Medical announced that it has completed the acquisition of phenox, a global neurointerventional company located in Germany, and its subsidiary femtos
.
The acquisition, with a total value of approximately EUR 500 million (including milestone payments), will create significant synergies in terms of product portfolio and market coverage, providing multi-faceted neurointerventions for patients in key markets such as China, the United States, Europe and Japan Technologies and Solutions
.
According to the data, Warby Medical Holdings Limited ("Woby Medical" or the "Company") is a global innovative medical technology company focused on the development and commercialization of neurointerventional medical device products for the treatment of stroke
.
For this acquisition, the relevant person in charge of Warby Medical said that it is a further extension of the cooperation between the two parties, and it is also a key step for Warby Medical to realize the company's vision
.
The combined company will take root in the two key markets of Europe and China, and further expand its presence in the US and Japan
.
Benefiting from the highly complementary product lines of the two companies, after the merger, Warby Medical will have a full-category, world-class neurointerventional product portfolio
.
With the expansion of product categories, enhancement of R&D capabilities and expansion of market coverage, Wobi Medical will also have a more significant competitive advantage, or become a large-scale enterprise in the field of neurointerventional devices
.
In recent years, industrial chain extension or product line expansion through investment and acquisition has become very common in the pharmaceutical field
.
It is understood that since the beginning of this year, there have been many local pharmaceutical companies that have expanded their product lines by buying and buying
.
For example, on March 9, Proton shares announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire Kaihui Medicine held by Ruizhi Chemical at a price of RMB 266 million in cash.
100% equity in the industry
.
After the completion of this transaction, the company will hold 100% equity of Kaihui Pharmaceutical, and Kaihui Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the scope of the company's consolidated financial statements
.
On February 18, Haoyuan Pharmaceutical announced that the company intends to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% of the shares of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
According to the data, Yaoyuan Pharmaceutical is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations to new drug developers, especially in the field of preparation CMC business
.
It is reported that this acquisition is expected to continue to extend the service chain of Haoyuan Pharmaceuticals, make up for shortcomings, and create a CRO/CDMO/CMO industry-wide service platform that integrates "intermediate-API-formulation"
.
On February 8, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center
.
The main business of Zhuhai Zhifan is to invest in Mingkang Bio, and it holds a registered capital of Mingkang Biology of RMB94,452,900 (of which RMB32,866,500 has not been paid), accounting for approximately 51% of the total registered capital of Mingkang Biology as at the date of this announcement
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The acquisition, with a total value of approximately EUR 500 million (including milestone payments), will create significant synergies in terms of product portfolio and market coverage, providing multi-faceted neurointerventions for patients in key markets such as China, the United States, Europe and Japan Technologies and Solutions
.
According to the data, Warby Medical Holdings Limited ("Woby Medical" or the "Company") is a global innovative medical technology company focused on the development and commercialization of neurointerventional medical device products for the treatment of stroke
.
For this acquisition, the relevant person in charge of Warby Medical said that it is a further extension of the cooperation between the two parties, and it is also a key step for Warby Medical to realize the company's vision
.
The combined company will take root in the two key markets of Europe and China, and further expand its presence in the US and Japan
.
Benefiting from the highly complementary product lines of the two companies, after the merger, Warby Medical will have a full-category, world-class neurointerventional product portfolio
.
With the expansion of product categories, enhancement of R&D capabilities and expansion of market coverage, Wobi Medical will also have a more significant competitive advantage, or become a large-scale enterprise in the field of neurointerventional devices
.
In recent years, industrial chain extension or product line expansion through investment and acquisition has become very common in the pharmaceutical field
.
It is understood that since the beginning of this year, there have been many local pharmaceutical companies that have expanded their product lines by buying and buying
.
For example, on March 9, Proton shares announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire Kaihui Medicine held by Ruizhi Chemical at a price of RMB 266 million in cash.
100% equity in the industry
.
After the completion of this transaction, the company will hold 100% equity of Kaihui Pharmaceutical, and Kaihui Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the scope of the company's consolidated financial statements
.
On February 18, Haoyuan Pharmaceutical announced that the company intends to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% of the shares of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
According to the data, Yaoyuan Pharmaceutical is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations to new drug developers, especially in the field of preparation CMC business
.
It is reported that this acquisition is expected to continue to extend the service chain of Haoyuan Pharmaceuticals, make up for shortcomings, and create a CRO/CDMO/CMO industry-wide service platform that integrates "intermediate-API-formulation"
.
On February 8, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center
.
The main business of Zhuhai Zhifan is to invest in Mingkang Bio, and it holds a registered capital of Mingkang Biology of RMB94,452,900 (of which RMB32,866,500 has not been paid), accounting for approximately 51% of the total registered capital of Mingkang Biology as at the date of this announcement
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
